Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What to do with TNF failures.

Edward C Keystone, Arthur Kavanaugh

    Expert Opinion on Drug Safety
    |March 30, 2005
    PubMed
    Summary
    This summary is machine-generated.

    Tumor necrosis factor (TNF) inhibitors have transformed rheumatoid arthritis treatment. However, some patients show poor response, necessitating clear definitions of treatment failure and exploration of alternative immunotherapies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    GRAPPA Debate: Is Plain Radiography in Psoriatic Disease Still Necessary?

    The Journal of rheumatology·2026
    Same author

    Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies.

    RMD open·2026
    Same author

    Psoriatic Arthritis Features and Risk of Cardiovascular Events: A Nationwide Cohort Study.

    Cureus·2025
    Same author

    Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.

    Nature medicine·2025
    Same author

    Pregnancy Outcomes After Maternal or Paternal Exposure to Tofacitinib Across Clinical Programs.

    The American journal of gastroenterology·2025
    Same author

    Challenges in Developing Treatment Guidelines in Psoriatic Arthritis.

    Rheumatic diseases clinics of North America·2025

    Area of Science:

    • Immunology
    • Rheumatology
    • Pharmacology

    Background:

    • Tumor necrosis factor (TNF) inhibitors represent a revolutionary therapeutic class for rheumatoid arthritis and systemic inflammatory diseases.
    • While highly effective for many, a significant patient subset exhibits primary non-response or develops suboptimal clinical outcomes.
    • Establishing clear criteria for TNF inhibitor therapy failure is crucial for both clinical practice and research advancement.

    Discussion:

    • The efficacy of TNF inhibitors in treating inflammatory conditions is well-established, yet patient variability in response necessitates further investigation.
    • Defining treatment failure is paramount for optimizing patient care and guiding therapeutic adjustments in rheumatology.
    • Understanding the mechanisms underlying non-response to TNF inhibitors is key to developing more effective treatment strategies.

    Related Experiment Videos

    Key Insights:

    • TNF inhibitors have significantly advanced the management of rheumatoid arthritis and related inflammatory disorders.
    • A portion of patients treated with TNF inhibitors do not achieve the desired therapeutic benefit.
    • Identifying non-responders is critical for timely intervention and exploring alternative treatment pathways.

    Outlook:

    • Research is actively exploring novel immunomodulatory targets beyond TNF for patients with refractory inflammatory diseases.
    • Future therapeutic strategies may involve targeting different components of the immune system to overcome non-response to current biologics.
    • The development of new treatments holds promise for improving outcomes for patients who do not respond to TNF inhibitors.